Potential adverse events with biologic response modifiers
- 31 August 2006
- journal article
- review article
- Published by Elsevier in Autoimmunity Reviews
- Vol. 5 (7) , 471-485
- https://doi.org/10.1016/j.autrev.2006.02.014
Abstract
No abstract availableKeywords
This publication has 83 references indexed in Scilit:
- Monoclonal antibodies and fusion proteins in medicineJournal of Allergy and Clinical Immunology, 2005
- Selection, design, and engineering of therapeutic antibodiesJournal of Allergy and Clinical Immunology, 2005
- Monoclonal antibody therapy of cancerNature Biotechnology, 2005
- Selecting and screening recombinant antibody librariesNature Biotechnology, 2005
- Monoclonal antibody successes in the clinicNature Biotechnology, 2005
- The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammationJournal of Allergy and Clinical Immunology, 2005
- Adverse reactions to biological modifiersCurrent Opinion in Allergy and Clinical Immunology, 2004
- Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthmaAnnals of Allergy, Asthma & Immunology, 2003
- Monoclonal antibodies in the clinicNature Biotechnology, 2001
- Anti-lgE Monoclonal Antibodies that Inhibit Allergen-Specific Histamine ReleaseInternational Archives of Allergy and Immunology, 1995